Payment overview · 2025
General Payments
$386.26
20 reported records · 10 companies
Healthcare provider profile · identity verified
Kathy Hamon, DO
Allopathic & Osteopathic Physicians|Family Medicine · SUMMERSVILLE, WV · NPI 1154312452
Verified facts
What the public records show
CMS Open Payments records show Kathy Hamon, DO received $386.26 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $146.55 | 37.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.50 | 17.7% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.94 | 9.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.92 | 6.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.82 | 5.9% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $21.36 | 5.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.37 | 4.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.29 | 4.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.93 | 4.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.58 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.26 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.50 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $66.08 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $58.91 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.75 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.98 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 347 | 80 |
| Montelukast Sodium | Montelukast Sodium | 307 | 76 |
| Omeprazole | Omeprazole | 280 | 67 |
| Potassium Chloride | Potassium Chloride | 270 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 49 |
| Furosemide | Furosemide | 212 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 48 |
| Losartan Potassium | Losartan Potassium | 186 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 49 |
| Lisinopril | Lisinopril | 182 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 160 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 22 |
| Meloxicam | Meloxicam | 144 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 33 |
| Buspirone Hcl | Buspirone Hcl | 131 | 28 |
| Methylprednisolone | Methylprednisolone | 120 | 64 |
| Metformin Hcl | Metformin Hcl | 112 | 26 |
| Ozempic | Semaglutide | 112 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 26 |
| Amoxicillin | Amoxicillin | 86 | 53 |
| Celecoxib | Celecoxib | 80 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 12 |
| Ibuprofen | Ibuprofen | 80 | 19 |
| Simvastatin | Simvastatin | 79 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 13 |
| Sucralfate | Sucralfate | 69 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 15 |
| Lovastatin | Lovastatin | 68 | 17 |
| Prednisone | Prednisone | 65 | 20 |
| Azithromycin | Azithromycin | 64 | 43 |
| Trazodone Hcl | Trazodone Hcl | 62 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 15 |
| Memantine Hcl | Memantine Hcl | 60 | suppressed |
| Aripiprazole | Aripiprazole | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 12 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 35 |
| Atenolol | Atenolol | 53 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | 15 |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 12 |
| Famotidine | Famotidine | 50 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 11 |
| Topiramate | Topiramate | 48 | 11 |
| Eliquis | Apixaban | 47 | 15 |
| Gabapentin | Gabapentin | 47 | suppressed |
| Torsemide | Torsemide | 47 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | 12 |
| Trimethoprim | Trimethoprim | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 16 |
| Meclizine Hcl | Meclizine Hcl | 42 | 14 |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 22 |
| Levofloxacin | Levofloxacin | 40 | 13 |
| Glipizide | Glipizide | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Naproxen | Naproxen | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Baclofen | Baclofen | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Nystatin | Nystatin | 30 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 13 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 12 |
| Cephalexin | Cephalexin | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 13 |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 12 |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.26 · 20 records | ABBVIE INC. | AIRSUPRA, CREON, FREESTYLE LIBRE 2, GVOKE HYPOPEN, Korlym, LINZESS, Ohtuvayre, Ozempic, Paradise Ultrasound Renal Denervation System, QULIPTA, RELISTOR, Rybelsus, SYNTHROID, UBRELVY, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error